Cyclopharm (ASX:CYC) 5-Year EBITDA Growth Rate : 0.00% (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Cyclopharm 5-Year EBITDA Growth Rate?

Cyclopharm's EBITDA per Share for the six months ended in Dec. 2023 was A$-0.01.

During the past 3 years, the average EBITDA Per Share Growth Rate was 18.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Cyclopharm was 18.20% per year. The lowest was -48.70% per year. And the median was -39.00% per year.

Competitive Comparison of Cyclopharm's 5-Year EBITDA Growth Rate

For the Medical Devices subindustry, Cyclopharm's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cyclopharm's 5-Year EBITDA Growth Rate Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cyclopharm's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Cyclopharm's 5-Year EBITDA Growth Rate falls into.

Cyclopharm 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Cyclopharm (ASX:CYC) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Cyclopharm 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Cyclopharm's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Cyclopharm (ASX:CYC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cyclopharm Ltd (ASX:CYC) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

Unit 4, 1 The Crescent, Kingsgrove, Sydney, NSW, AUS, 2208

Website

https://cyclopharm.com.au

Cyclopharm Ltd is a company that engages in the manufacture and sale of medical equipment and radiopharmaceuticals, including associated research and development. It operates through the following segments. The Technegas segment involves supplying diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism, and a distributor of products to the diagnostic imaging sector. The Molecular Imaging segment offers to produce radiopharmaceuticals to be used by physicians in the detection of cancer, neurological disorders, and cardiac disease. The firm generates maximum revenue from the Technegas segment.

Cyclopharm (ASX:CYC) Headlines

No Headlines